p53 Protein Transduction Therapy: Successful Targeting and Inhibition of the Growth of the Bladder Cancer Cells
Monday, 02 January 2006
Introduction: Virus-mediated gene therapy for bladder cancer has some problems, such as efficiency of gene delivery and safety issues. We have reported that poly-arginine peptide (11R) has the ability to increase protein transduction in cells. Here, we show that p53 protein transduction using 11R is useful for targeting to bladder tumors and suppressing the growth of bladder cancer cells.
read more
|
European Urology - Antitumor Activity of the Antimicrobial Peptide Magainin II against Bladder Cancer Cell Lines
Wednesday, 28 June 2006
Volume 50, Issue 1, Pages 141-147 (July 2006) Abstract - Objective: Magainin II belongs to a family of antimicrobial peptides and has been shown to exhibit antibiotic activity in a wide range of organisms.
read more
|
Watchful Waiting for Low-Grade Ta Bladder Tumours: The Idea would have been Unacceptable 30 Years Ago, but Nowadays We are Highly Interested in the Results of This Study Exploring It
Wednesday, 08 February 2006
In the 1970s, when intravesical chemotherapy and BCG were developed, doctors advocated more aggressive treatment against superficial bladder tumours. Coagulation alone was unacceptable; random biopsies were obligatory, and an intravenous urography had to be made in all cases. At that time cystectomy specimens were demonstrated to show superficial bladder tumours in about 30% of the cases. Invasive bladder tumours were considered the end stage of superficial bladder tumour disease, and early detection of high-grade tumours could save lives. Later, second resection, early after initial TUR was recommended.
read more
|
European Urology - Plasmacytoid Urothelial Carcinoma of the Urinary Bladder: Report of Seven New Cases
Wednesday, 25 October 2006
Volume 50, Issue 5, Pages 1111-1114 (November 2006) Abstract - Introduction: Plasmacytoid urothelial carcinoma (PUC) is a rare tumor of the urinary bladder. Its clinical and histopathological features have not been well characterized.
read more
|
Prevention of Bladder Cancer: A Review
Wednesday, 01 February 2006
Introduction: Bladder cancer represents an ideal tumor model to test and apply cancer prevention strategies. In addition to reviewing the epidemiology of transitional cell carcinoma (TCC), we review the current status and the future directions of bladder cancer prevention.
read more
|
European Urology - Search for Biomarkers of Aggressiveness in Bladder Cancer
Wednesday, 28 June 2006
Volume 50, Issue 1, Pages 20-22 (July 2006) A noninvasive, highly accurate diagnostic test capable of predicting the probability of disease recurrence and progression has long been desired in the field of urologic oncology.
read more
|
European Urology - Thoughts on Delaying Cystectomy
Thursday, 23 November 2006
Volume 50, Issue 6, Pages 1151-1152 (December 2006) Article Outline: The literature review of Fahmy et al. [1] reveals that the majority of studies on bladder cancer confirm that pretreatment delays are associated with worse outcome. The studies suggested a window of opportunity of less than 12 wk from diagnosis of invasive disease to radical cystectomy.
read more
|
Management of BCG “Failures”
Saturday, 06 May 2006
Bacillus Calmette-Guérin (BCG) into the bladder has been demonstrated as an efficacious adjuvant treatment for superficial bladder cancer. BCG is the most effective regimen for the management of superficial disease, including cellular immune stimulation (CIS). However, the treatment fails in 30%–40% of patients, and 30%–40% of those who initially respond relapse. The reasons for an abnormal response may be insufficient or inappropriate CIS or detrimental response because the immune system has been overstimulated [1].
read more
|
European Urology - Gene Expression in Normal Urothelium Depends on Location within the Bladder: A Possible Link to Bladder Carcinogenesis
Wednesday, 19 July 2006
Volume 50, Issue 2, Pages 290-301 (August 2006) 1. Introduction: Transformation of the normal bladder epithelium is accompanied by a plethora of molecular and biochemical changes [1], [2], [3]; the first of these genetic alterations may precede the diagnosis of cancer by several decades.
read more
|
European Urology - Radical Cystectomy – Often Too Late? Yes, But …
Thursday, 23 November 2006
Volume 50, Issue 6, Pages 1129-1138 (December 2006)Article Outline - The editors of European Urology elected to reprint this manuscript, which was initially published almost 20 yr ago and continues to contain important messages. Not only was the Mainz group one of the initiators advocating radical cystectomy as the optimal treatment for invasive bladder cancer, but they also made the following important points that are still true to this day.
read more
|
European Urology - Foreseeing Cancer Metastases
Wednesday, 20 September 2006
Volume 50, Issue 4, Pages 648-649 (October 2006) Metastatic potential reveals the true nature of cancer. In more advanced bladder cancer metastases occur during disease follow-up in >50% of cases, despite extensive local treatment.
read more
|
European Urology - Hybrid SPECT-CT: An Additional Technique for Sentinel Node Detection of Patients with Invasive Bladder Cancer
Wednesday, 28 June 2006
Volume 50, Issue 1, Pages 83-91 (July 2006)Abstract - Objective:
To explore the feasibility of performing lymphoscintigraphy combined with computed tomography CT) for preoperative detection of sentinel lymph nodes in patients with invasive bladder cancer.
read more
|
Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials
Wednesday, 01 March 2006
Objectives: To provide tables that allow urologists to easily calculate a superficial bladder cancer patient's short- and long-term risks of recurrence and progression after transurethral resection.
read more
|
European Urology - The Predictive Value of p53, p27kip1, and α-catenin for Progression in Superficial Bladder Carcinoma
Wednesday, 28 June 2006
Volume 50, Issue 1, Pages 76-82 (July 2006)
1. Introduction: In Europe and the United States, each year, approximately 20 new cases of bladder cancer per 100,000 persons are diagnosed, resulting in 5/100,000 persons dying from this disease annually [1].
read more
|
European Urology - Should Bladder Biopsies be Performed Routinely after Bacillus Calmette-Guérin Treatment for High-Risk Superficial Transitional Cell Cancer of the Bladder?
Friday, 01 September 2006
Volume 50, Issue 3, Pages 516-520 (September 2006) Abstract -
Objective:
After endoscopic resection of high-grade superficial urothelial neoplasms (Ta, T1 or Tis), adjuvant bacillus Calmette-Guérin (BCG) therapy is performed routinely to avoid recurrence and/or progression. Vesical biopsies often are performed to assess the efficacy of treatment. The aim of our study was to evaluate the usefulness of these biopsies.
read more
|
European Urology - Precystectomy Nomogram for Prediction of Advanced Bladder Cancer Stage
Thursday, 23 November 2006
Volume 50, Issue 6, Pages 1254-1262 (December 2006) Abstract - Objective:To evaluate precystectomy prediction of pT and pN stages at cystectomy.
read more
|
Evaluation of Chemotherapy with Magnetic Resonance Imaging in Patients with Regionally Metastatic or Unresectable Bladder Cancer
Monday, 03 April 2006
Objectives: To determine whether the failure of chemotherapy in patients with regionally metastatic or unresectable transitional cell carcinoma (TCC) of the bladder can be predicted early in the course of chemotherapy with magnetic resonance (MR) imaging.
read more
|
The Prognostic Value of E-Cadherin, α-, β-, and γ-Catenin in Urothelial Cancer of the Upper Urinary Tract
Saturday, 06 May 2006
Objective: To determine the value of loss of the expression of E-cadherin and cadherin-associated molecules as useful markers for both prognosis and bladder recurrence in patients with upper urinary tract cancer.
read more
|
European Urology - Molecular and Immunohistochemical Analysis of the Prognostic Value of Cell-Cycle Regulators in Urothelial Neoplasms of the Bladder
Tuesday, 29 August 2006
Volume 50, Issue 3, Pages 506-515 (September 2006)
Abstract -
Objective:
To evaluate the prognostic and predictive value of molecular and immunohistochemical markers related to cell-cycle control in terms of recurrence, progression, and survival in urothelial neoplasms of the bladder (UNB).
read more
|
Infrequent Microsatellite Instability in Urothelial Cell Carcinoma of the Bladder in Young Patients
Monday, 03 April 2006
Objective: Defects in the DNA mismatch repair result in microsatellite instability (MSI), which characterise most tumours related to the hereditary non-polyposis colorectal cancer syndrome and some sporadic tumours. Several studies have reported the occurrence of MSI in urothelial cell carcinoma (UCC) of the bladder with a particularly high incidence in tumours from young patients. In this study, we have evaluated the occurrence of MSI in primary bladder UCC arising in seventeen young patients selected for being below 45 years of age at diagnosis.
read more
|
Intravesical Instillations with Bacillus Calmette-Guérin for the Treatment of Carcinoma In Situ Involving Prostatic Ducts
Saturday, 06 May 2006
Objective: Bacillus Calmette-Guérin (BCG) has proven its efficacy in the treatment of carcinoma in situ (CIS) of the prostatic urethra. We performed a retrospective study to evaluate the use of intravesical instillations of BCG in patients with carcinoma in situ involving prostatic ducts after complete transurethral resection (TUR).
read more
|
Detection of Immune Responses Against Urinary Bladder Cancer in Sentinel Lymph Nodes
Monday, 02 January 2006
Objective: The lymphatic drainage from a tumour is received in the sentinel node where the immune system encounters tumour derived antigens. We investigated anti-tumoural lymphocyte function in sentinel nodes from patients with urinary bladder cancer.
read more
|
European Urology - Focal S100A4 Protein Expression Is an Independent Predictor of Development of Metastatic Disease in Cystectomized Bladder Cancer Patients
Thursday, 21 September 2006
Volume 50, Issue 4, Pages 777-785 (October 2006) 1. IntroductionSubclinical spread of cancer cells, present at the time of diagnosis and definite treatment, constitutes the biggest threat to patients with seemingly localized muscle-invasive bladder cancer. Despite radical cystectomy, offering excellent local control, around 30–50% of these patients still succumb to distant metastases.
read more
|
Management of BCG Failures in Superficial Bladder Cancer: A Review
Saturday, 06 May 2006
Objective: Review management of bacillus Calmette-Guérin (BCG) failures in superficial bladder cancer.
read more
|
Lymph Node Metastasis in Bladder Cancer
Monday, 02 January 2006
Objective: We reviewed the literature on nodal staging in patients with bladder cancer treated with radical cystectomy and lymphadenectomy.
read more
|
European Urology - Elevated Microsatellite Instability at Selected Tetranucleotide Repeats does not Correlate with Clinicopathologic Features of Bladder Cancer
Thursday, 21 September 2006
Volume 50, Issue 4, Pages 770-776 (October 2006) Abstract -
Introduction:
The aim of the present study was to evaluate whether elevated microsatellite instability (MSI) at selected tetranucleotide repeats (EMAST) is associated with clinicopathologic and molecular parameters in urinary bladder cancer (BC).
read more
|
Working Capacity and Well-Being after Radical Cystectomy with Continent Cutaneous Diversion
Monday, 03 April 2006
Objectives: The primary aim was to compare the working capacity in patients with continent urinary diversion with a control group. Secondary aims were to assess the changes in electrolyte and acid-base homeostasis and the functional status during strenuous physical activity, and finally, the well-being in the two groups.
read more
|
Urinary Hyaluronan as a Marker for the Presence of Residual Transitional Cell Carcinoma of the Urinary Bladder
Monday, 02 January 2006
Objective: The purpose of this report is to evaluate the value of urinary hyaluronan (HA) as a maker of residual transitional cell carcinoma (TCC).
read more
|
European Urology - Supra-ampullar Cystectomy and Ileal Neobladder
Thursday, 23 November 2006
Volume 50, Issue 6, Pages 1223-1233 (December 2006) Abstract - Objective: This article describes both the open and laparoscopic operative techniques of supra-ampullar cystectomy (SAC).
read more
|
Current Practice in the Management of Superficial Bladder Cancer in the Netherlands and Belgian Flanders: A Survey
Wednesday, 01 March 2006
Objectives: Because there is no national guideline for the diagnosis, therapy and follow up of (superficial) bladder cancer in the Netherlands and Belgium, the actual patient management may differ between urologists. The purpose of this study is to get insight in the current way urologists diagnose, treat and follow patients with superficial bladder cancer.
read more
|
European Urology - Delay in the Surgical Treatment of Bladder Cancer and Survival: Systematic Review of the Literature
Thursday, 23 November 2006
Volume 50, Issue 6, Pages 1176-1182 (December 2006) 1. Introduction: Bladder cancer is the sixth most common noncutaneous cancer in Canada. It is the 8th most common cause of cancer death in males and the 13th in females [1].
read more
|
